Letter: Helicobacter pylori in proton pump inhibitor‐associated biliary disease

R E FE R E N C E S 1. McPherson SJ, Hammond CJ. Letter: the Shock Index and predicting outcomes in patients with upper gastrointestinal bleeding. Aliment Pharmacol Ther. 2020;51:311-312. 2. Saffouri E, Blackwell C, Laursen SB, et al. The Shock Index is not accurate at predicting outcomes in patients with upper gastrointestinal bleeding. Aliment Pharmacol Ther. 2020;51:253-260. 3. Hearnshaw SA, Logan RFA, Lowe D, Travis SPL, Murphy MF, Palmer KR. Use of endoscopy for management of acute upper gastrointestinal bleeding in the UK: results of a nationwide audit. Gut. 2010;59:1022-1029. 4. Laursen SB, Laine L, Dalton H, et al. The International Bleeding Risk Score: a new risk score that can accurately predict mortality in patients with upper GI bleeding. Gastroenterology. 2017;152(Suppl 1):S149-S150. 5. Laursen SB, Oakland K, Laine L, et al. External validation of the international bleeding risk score in both upper and lower GI bleeding: an international multicentre study. UEGJ. 2018;6(8S):A126-127.

[1]  J. K. Lee,et al.  Use of proton pump inhibitors and the risk of cholangitis: a nationwide cohort study , 2019, Alimentary pharmacology & therapeutics.

[2]  E. Dardiotis,et al.  A perspective on risk factors for esophageal adenocarcinoma: emphasis on Helicobacter pylori infection , 2019, Annals of the New York Academy of Sciences.

[3]  Prashanth Rawla,et al.  Epidemiology of gallbladder cancer , 2019, Clinical and experimental hepatology.

[4]  Youming Li,et al.  Helicobacter Pylori infection of the gallbladder and the risk of chronic cholecystitis and cholelithiasis: A systematic review and meta‐analysis , 2018, Helicobacter.

[5]  Fei Ma,et al.  Helicobacter pylori and 17β-estradiol induce human intrahepatic biliary epithelial cell abnormal proliferation and oxidative DNA damage. , 2017, Hepatobiliary & pancreatic diseases international : HBPD INT.

[6]  U. Ijaz,et al.  Comparison of the human gastric microbiota in hypochlorhydric states arising as a result of Helicobacter pylori-induced atrophic gastritis, autoimmune atrophic gastritis and proton pump inhibitor use , 2017, bioRxiv.

[7]  Antonio Gasbarrini,et al.  Extragastric Diseases and Helicobacter pylori , 2013, Helicobacter.

[8]  J. Sung,et al.  Helicobacter species and hepatobiliary diseases , 2002 .

[9]  E. Kazakos,et al.  The Emerging Role of Helicobacter Pylori-Induced Metabolic Gastrointestinal Dysmotility and Neurodegeneration. , 2017, Current molecular medicine.

[10]  J. Kountouras,et al.  Comment on "The correlation of Helicobacter pylori with the development of cholelithiasis and cholecystitis: the results of a prospective clinical study in Saudi Arabia". , 2016, European review for medical and pharmacological sciences.